President Trump’s drug pricing plan will not include a call for Medicare to negotiate drug prices, a leading Democratic idea that Trump previously supported, a senior administration official said Thursday.
“We’re not calling for Medicare negotiation in the way that Democrats have called for,” the official said on a call with reporters previewing Trump’s speech on drug prices scheduled Friday.
However, the official said there will be other proposals to increase competition in Medicare, likely using private sector players rather than Medicare directly negotiating prices.
via The Hill.
Related Reading:
Trump Favors Big Pharma Profits Over Seniors Prescription Drug Savings.
- While the President’s new plan to curtail drug costs reportedly contains some productive measures – including requiring insurers and pharmacy benefit managers (PBMs) who act as middlemen to pass manufacturer rebates onto consumers and limiting reimbursement for Medicare outpatient drugs beyond the rate of inflation – the failure to empower Medicare to bring prescription prices down is a glaring omission, but not a surprising one.






